利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

83 条记录 (耗时 0.024 秒)

    Aminomethyl-4-imidazoles
    25.
    发明授权
    Aminomethyl-4-imidazoles 失效
    氨基甲基-4-咪唑

    公开(公告)号：US08586617B2

    公开(公告)日：2013-11-19

    申请号：US11872203

    申请日：2007-10-15

    申请人： Guido Galley ,  Annick Goergler ,  Katrin Groebke Zbinden ,  Roger Norcross ,  Henri Stalder

    发明人： Guido Galley ,  Annick Goergler ,  Katrin Groebke Zbinden ,  Roger Norcross ,  Henri Stalder

    IPC分类号： A61K31/417 ,  C07D233/64

    CPC分类号： C07D233/64

    摘要： The present invention relates to amino-4-methyl imidazoles and pharmaceutically-acceptable salts thereof. The compound may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

    摘要翻译： 本发明涉及氨基-4-甲基咪唑及其药学上可接受的盐。 该化合物可用于治疗抑郁症，焦虑障碍，双相情感障碍，注意力缺陷多动障碍（ADHD），应激相关疾病，精神病性精神障碍如精神分裂症，神经系统疾病如帕金森病，神经变性疾病如阿尔茨海默病， 癫痫，偏头痛，高血压，药物滥用和代谢障碍如进食障碍，糖尿病，糖尿病并发症，肥胖症，血脂异常，能量消耗和同化障碍，体温平衡紊乱和失调，睡眠和昼夜节律紊乱以及心血管疾病 。

    2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as TAAR-ligands
    27.
    发明授权
    2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as TAAR-ligands 失效
    2-氮杂环丁烷甲烷胺和2-吡咯烷甲烷胺作为TAAR-配体

    公开(公告)号：US08389507B2

    公开(公告)日：2013-03-05

    申请号：US12176456

    申请日：2008-07-21

    申请人： Guido Galley ,  Annick Goergler ,  Katrin Groebke Zbinden ,  Roger Norcross ,  Henri Stalder

    发明人： Guido Galley ,  Annick Goergler ,  Katrin Groebke Zbinden ,  Roger Norcross ,  Henri Stalder

    IPC分类号： A01N43/00 ,  A61K31/397

    CPC分类号： C07D205/04 ,  C07D207/09

    摘要： The present invention relates to compounds of formula I wherein R1, R2, R3, Ar, n and o are as defined herein and to their pharmaceutically acceptable active salts. Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1 and are useful for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

    摘要翻译： 本发明涉及其中R 1，R 2，R 3，Ar，n和o如本文所定义的式I化合物及其药学上可接受的活性盐。 式I化合物对微量胺相关受体（TAAR）具有良好的亲和力，尤其对于TAAR1，可用于治疗抑郁症，焦虑障碍，双相情感障碍，注意缺陷多动障碍（ADHD），应激相关疾病，精神病性 诸如精神分裂症，神经系统疾病如帕金森病，神经变性疾病如阿尔茨海默氏病，癫痫，偏头痛，高血压，药物滥用和代谢性疾病如进食障碍，糖尿病，糖尿病并发症，肥胖症，血脂异常，能量消耗和同化障碍等疾病 ，体温平衡紊乱和失眠，睡眠障碍和昼夜节律，以及心血管疾病。

    2-AMINOOXAZOLINES AS TAAR1 LIGANDS
    29.
    发明申请
    2-AMINOOXAZOLINES AS TAAR1 LIGANDS 审中-公开
    2-AMINOOXAZOLINES as TAAR1 LIGANDS

    公开(公告)号：US20100311798A1

    公开(公告)日：2010-12-09

    申请号：US12789484

    申请日：2010-05-28

    申请人： Guillaume Décoret ,  Guido Galley ,  Katrin Groebke Zbinden ,  Roger Norcross

    发明人： Guillaume Décoret ,  Guido Galley ,  Katrin Groebke Zbinden ,  Roger Norcross

    IPC分类号： A61K31/421 ,  C07D263/28

    CPC分类号： C07D263/28

    摘要： The invention relates to compounds of formula wherein R1, R2, R2′, X, Y, andn are as defined in the specification or to a pharmaceutically suitable acid addition salt thereof. The compounds of formula I are active on the TAAR1 receptor and are therefore suitable for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

    摘要翻译： 本发明涉及下式的化合物，其中R1，R2，R2'，X，Y和n如说明书中所定义或其药学上合适的酸加成盐。 式I化合物对TAAR1受体具有活性，因此适用于治疗抑郁症，焦虑障碍，双相情感障碍，注意缺陷多动障碍，应激相关疾病，精神病，精神分裂症，神经系统疾病，帕金森病，神经变性疾病 ，阿尔茨海默病，癫痫，偏头痛，药物滥用和代谢紊乱，饮食失调，糖尿病，糖尿病并发症，肥胖症，血脂异常，能量消耗和同化障碍，体温平衡紊乱和失调，睡眠和昼夜节律紊乱以及心血管 疾病